Scynexis Europe renamed Selcia following sale
sold its subsidiary in the United Kingdom to its UK management in a
move that allows Selcia to provide custom radiolabeling, chemistry
and analytics services to a broader customer base.
The move will also allow Scynexis to concentrate on its core business and partners enhancing its growing presence in the global pharmaceutical marketplace and continue to build discovery collaborations with major companies.
Scynexis, a chemistry-focused drug discovery and development company, have made a name for themselves, providing services in the form of research teams in the field of medicinal chemists, computational chemists, analytical chemists and bioanalytical scientists to work on with customers on projects from hit to candidate selection.
The company have a number of agreements set in place with businesses such as Roche, Merck and Co and Teijin Pharma.
Selcia already provides custom radiolabeling, analytical technologies and their integration with synthetic chemistry. The company also produces radiolabeled versions of pharmaceutical and agricultural drug candidates by GMP principles. The products come with a GLP quality data pack and are suitable for use in human trials.
"We are in the process of offering new services such as metabolomics and metabolic profiling, and their integration with chemistry," said Dr. Hans Fliri, the Managing Director of Selcia.
"We plan to increase capacity in this business and to invest in new development programs in the future. This will create opportunities for new financial investment in the company."
